Antiplatelet agents in hemodialysis

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Cardiovascular disease (CVD) is the leading cause of death in chronic renal failure (CRF) patients.
• CRF patients, especially those on hemodialysis (HD), have significantly higher risks of myocardial infarction (MI) and coronary artery disease (CAD) compared to the general population.
• Antiplatelet agents (AA) are crucial for managing various cardiovascular conditions but their role in CRF requires careful consideration.

Purpose of the Study:

• To evaluate the efficacy and safety of antiplatelet agents (AA) in patients with chronic renal failure (CRF).
• To determine the role of AA in primary and secondary prevention of cardiovascular events in hemodialysis (HD) patients.
• To assess the risk-benefit profile of aspirin and dual antiplatelet therapy in CRF patients.

Main Methods:

• Review of existing clinical data and studies on antiplatelet agent use in CRF and hemodialysis populations.
• Analysis of outcomes related to primary and secondary cardiovascular event prevention.
• Evaluation of hemorrhagic risk associated with antiplatelet therapy in this high-risk group.

Main Results:

• Current evidence does not support AA for primary prevention of cardiovascular mortality in hemodialysis patients.
• Studies suggest aspirin may reduce mortality in dialysis patients post-MI (secondary prevention).
• Dual AA therapy (aspirin plus clopidogrel) shows increased bleeding risk without significant cardiovascular benefit; data on new AA drugs are insufficient.

Conclusions:

• Aspirin may be considered for secondary CVD prevention in hemodialysis patients due to high atherosclerotic risk.
• Bleeding risk must be carefully evaluated in CRF patients, particularly before initiating dual AA treatment.
• Further research is needed to clarify the optimal use of antiplatelet agents in the CRF population.